|
US3959008A
(en)
|
1974-06-24 |
1976-05-25 |
Cities Service Company |
Carbon black
|
|
CA2364279A1
(en)
|
1999-03-05 |
2000-09-08 |
Diacrin, Inc. |
Methods for improving graft acceptance in a recipient by administration of a cytokine profile altering agent
|
|
EP1397382B1
(en)
*
|
2001-05-31 |
2008-08-06 |
Novartis AG |
Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
|
|
DK1454138T3
(da)
|
2001-12-04 |
2012-02-13 |
Merck Patent Gmbh |
Immunocytokiner med moduleret selektivitet
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
|
JP5764127B2
(ja)
|
2009-08-17 |
2015-08-12 |
ロシュ グリクアート アーゲー |
標的化イムノコンジュゲート
|
|
CA2795349C
(en)
|
2010-04-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Targeted pyrrolobenzodiazepine conjugates
|
|
SG192673A1
(en)
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
KR20130118941A
(ko)
|
2011-02-10 |
2013-10-30 |
로슈 글리카트 아게 |
면역치료법
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EP2748202B1
(en)
|
2011-08-23 |
2018-07-04 |
Roche Glycart AG |
Bispecific antigen binding molecules
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
MY175687A
(en)
|
2012-08-07 |
2020-07-06 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
US9159294B2
(en)
|
2014-01-31 |
2015-10-13 |
Google Inc. |
Buttonless display activation
|
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
US10934346B2
(en)
*
|
2014-02-14 |
2021-03-02 |
Bellicum Pharmaceuticals, Inc. |
Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
|
|
PT3172227T
(pt)
|
2014-07-21 |
2019-12-06 |
Delinia Inc |
Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis
|
|
DK3186283T3
(da)
|
2014-08-29 |
2020-03-02 |
Hoffmann La Roche |
Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
|
|
US20160362469A1
(en)
*
|
2015-06-12 |
2016-12-15 |
Tianxin Wang |
Methods for protein modification in pharmaceutical applications
|
|
US10508143B1
(en)
*
|
2015-10-30 |
2019-12-17 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
IL260532B2
(en)
*
|
2016-01-11 |
2023-12-01 |
Univ Leland Stanford Junior |
Chimeric proteins- containing systems and uses thereof in regulating gene expression
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
JP6911044B2
(ja)
|
2016-03-16 |
2021-07-28 |
シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ |
呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ
|
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
RU2769282C2
(ru)
*
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
JP7033328B2
(ja)
|
2016-08-16 |
2022-03-10 |
エピムアブ バイオセラピューティクス インコーポレイテッド |
一価の非対称タンデムＦａｂ二重特異性抗体
|
|
BR112019005964A2
(pt)
|
2016-09-27 |
2019-06-18 |
Epicentrx, Inc. |
proteínas de fusão imunomoduladoras
|
|
CN107915777A
(zh)
|
2016-10-09 |
2018-04-17 |
泰州迈博太科药业有限公司 |
一种重组免疫细胞因子及其应用
|
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
MY201482A
(en)
|
2017-04-03 |
2024-02-26 |
Hoffmann La Roche |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
|
CN110505883A
(zh)
|
2017-04-13 |
2019-11-26 |
豪夫迈·罗氏有限公司 |
供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
|
|
MY206158A
(en)
|
2017-05-24 |
2024-12-02 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
US20200140547A1
(en)
|
2017-05-26 |
2020-05-07 |
The Johns Hopkins University |
Multifunctional antibody-ligand traps to modulate immune tolerance
|
|
JP2020522495A
(ja)
|
2017-05-30 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
|
|
CN111201035A
(zh)
|
2017-06-19 |
2020-05-26 |
梅迪塞纳医疗股份有限公司 |
Il-2超激动剂、激动剂及其融合体的用途和方法
|
|
JP2020530280A
(ja)
|
2017-07-03 |
2020-10-22 |
トルク セラピューティクス， インコーポレイテッド |
免疫刺激性融合分子およびその使用
|
|
KR20240141853A
(ko)
*
|
2017-08-03 |
2024-09-27 |
신톡스, 인크. |
자가면역 질환의 치료를 위한 사이토카인 접합체
|
|
JP7710706B2
(ja)
|
2017-09-25 |
2025-07-22 |
シーフイダ ファーマシューティカル グループ （チーリン） カンパニー リミテッド |
癌治療のための方法及び組成物
|
|
WO2019090330A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
WO2019129053A1
(zh)
|
2017-12-26 |
2019-07-04 |
南京金斯瑞生物科技有限公司 |
以抗体Fc区为骨架的融合蛋白二聚体及其应用
|
|
TW201938196A
(zh)
|
2018-01-18 |
2019-10-01 |
美商南特生物科學股份有限公司 |
融合蛋白擴展
|
|
WO2019147837A2
(en)
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine fusion proteins
|
|
EP3762406A2
(en)
|
2018-03-09 |
2021-01-13 |
Askgene Pharma, Inc. |
Cytokine prodrugs
|
|
PE20210313A1
(es)
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
|
WO2019222296A1
(en)
*
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
AU2019271148B9
(en)
*
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
EP3802619A1
(en)
|
2018-06-08 |
2021-04-14 |
F. Hoffmann-La Roche AG |
Peptidic linker with reduced post-translational modification
|
|
AU2019288484B2
(en)
|
2018-06-22 |
2024-06-20 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
AU2019301070B2
(en)
|
2018-07-09 |
2025-09-11 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
|
US20200026890A1
(en)
|
2018-07-18 |
2020-01-23 |
Brandon Iglesias |
Smart Equipment Energizer and Method for Using
|
|
US20210221864A1
(en)
|
2018-08-24 |
2021-07-22 |
City Of Hope |
Masked cytokine conjugates
|
|
US20220002370A1
(en)
*
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
TWI840433B
(zh)
|
2018-10-29 |
2024-05-01 |
大陸商北京強新生物科技有限公司 |
新穎合理設計的蛋白質組合物
|
|
EP3927728A2
(en)
|
2019-02-21 |
2021-12-29 |
Xencor, Inc. |
Untargeted and targeted il-10 fc-fusion proteins
|
|
CN121652287A
(zh)
|
2019-03-06 |
2026-03-13 |
德卡生物科学公司 |
Il-10变体分子和治疗炎性疾病和肿瘤的方法
|
|
US11718673B2
(en)
|
2019-04-01 |
2023-08-08 |
Immetas Therapeutics, Inc. |
Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein
|
|
EP3955957A1
(en)
|
2019-04-15 |
2022-02-23 |
Qwixel Therapeutics LLC |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
US20220227837A1
(en)
|
2019-05-24 |
2022-07-21 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2 compositions and methods of use thereof
|
|
EP3980051A4
(en)
|
2019-06-05 |
2023-09-13 |
Asher Biotherapeutics, Inc. |
FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
|
|
WO2020259536A1
(zh)
|
2019-06-24 |
2020-12-30 |
南京金斯瑞生物科技有限公司 |
单克隆抗体-细胞因子融合蛋白二聚体及其应用
|
|
EP3997115A4
(en)
|
2019-07-12 |
2023-11-22 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2 compositions and methods of use thereof
|
|
BR112022001320A2
(pt)
|
2019-07-25 |
2022-04-12 |
Univ Chicago |
Composições e métodos compreendendo agentes terapêuticos ativados por protease
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
CA3148505A1
(en)
|
2019-08-12 |
2021-02-18 |
AskGene Pharma, Inc. |
Novel il-2 fusion molecules
|
|
JP2022544405A
(ja)
|
2019-08-15 |
2022-10-18 |
アイジーエム バイオサイエンシズ インコーポレイテッド |
免疫刺激性多量体型結合分子
|
|
US20220289822A1
(en)
|
2019-08-21 |
2022-09-15 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
AU2020353235A1
(en)
|
2019-09-28 |
2022-03-31 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
|
MX2022005666A
(es)
|
2019-11-14 |
2022-10-07 |
Werewolf Therapeutics Inc |
Polipeptidos de citocina activables y metodos de uso de los mismos.
|
|
AU2020397416A1
(en)
|
2019-12-03 |
2022-07-14 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use in treating hepatitis B infection
|
|
CN121517534A
(zh)
|
2019-12-13 |
2026-02-13 |
辛德凯因股份有限公司 |
Il-2直向同源物及其使用方法
|
|
CA3165927A1
(en)
|
2020-01-11 |
2021-07-15 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
JP2023514152A
(ja)
|
2020-02-06 |
2023-04-05 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｌ－１０およびその使用
|
|
EP4114857A4
(en)
|
2020-03-06 |
2024-06-26 |
University of Pittsburgh - of the Commonwealth System of Higher Education |
Serum albumin binding nanobody compositions and methods for using the same
|
|
JP2023527690A
(ja)
|
2020-05-11 |
2023-06-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
改変ｐｂｍｃと免疫抱合体との併用療法
|
|
IL298136A
(en)
|
2020-05-13 |
2023-01-01 |
Bonum Therapeutics Inc |
Preparations of protein complexes and methods of using them
|
|
CA3178657A1
(en)
|
2020-05-19 |
2021-11-25 |
William Winston |
Activatable il-12 polypeptides and methods of use thereof
|
|
US20230181471A1
(en)
|
2020-07-09 |
2023-06-15 |
Hoffmann-La Roche Inc. |
Concentrated compositions of proteins, their preparation and use thereof
|
|
US11028174B1
(en)
|
2020-07-28 |
2021-06-08 |
Lepu Biopharma Co., Ltd. |
Bifunctional molecules targeting PD-L1 and TGF-β
|
|
CN116194480A
(zh)
|
2020-08-13 |
2023-05-30 |
百时美施贵宝公司 |
将il-2重定向到目的靶细胞的方法
|
|
US11865082B2
(en)
|
2020-09-09 |
2024-01-09 |
Hoffmann-La Roche Inc. |
Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
|
|
KR20230112632A
(ko)
|
2020-10-23 |
2023-07-27 |
애셔 바이오테라퓨틱스, 인크. |
면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
|
|
KR20230117122A
(ko)
|
2020-12-04 |
2023-08-07 |
에프. 호프만-라 로슈 아게 |
pH 의존성 돌연변이체 인터류킨-2 폴리펩티드
|
|
WO2022125694A1
(en)
|
2020-12-09 |
2022-06-16 |
Asher Biotherapeutics, Inc. |
Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
|
|
KR20230129983A
(ko)
|
2020-12-09 |
2023-09-11 |
애셔 바이오테라퓨틱스, 인크. |
조작된 세포 요법을 위한 표적화된 사이토카인 구축물
|
|
WO2022150791A2
(en)
|
2021-01-11 |
2022-07-14 |
Synthekine, Inc. |
Compositions and methods related to il2 receptor binding
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
WO2022155263A2
(en)
|
2021-01-12 |
2022-07-21 |
Askgene Pharma Inc. |
Chimeric molecules comprising il-12 agonist polypeptide
|
|
US20240076355A1
(en)
|
2021-01-14 |
2024-03-07 |
AskGene Pharma, Inc. |
Interferon Prodrugs and Methods of Making and Using the Same
|
|
CN117500824A
(zh)
|
2021-02-01 |
2024-02-02 |
奥美药业有限公司 |
包含IL-10或TGF-β激动剂多肽的嵌合分子
|
|
WO2022174102A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
|
EP4304724A1
(en)
|
2021-03-09 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
|
|
WO2022189377A1
(en)
|
2021-03-09 |
2022-09-15 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
|
|
CN118043079A
(zh)
|
2021-06-17 |
2024-05-14 |
格治(香港)生物科技有限公司 |
免疫缀合物分子及其相关方法和组合物
|
|
EP4358990A4
(en)
|
2021-06-24 |
2025-05-21 |
Bristol-Myers Squibb Company |
TRANSFORMING GROWTH FACTOR BETA LIGAND TRAP FOR DISEASE TREATMENT
|
|
US20230201364A1
(en)
|
2021-07-09 |
2023-06-29 |
Bright Peak Therapeutics Ag |
Antibody conjugates and manufacture thereof
|
|
AU2022306974A1
(en)
|
2021-07-09 |
2024-01-04 |
Bright Peak Therapeutics Ag |
Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
|
|
US20230201365A1
(en)
|
2021-07-09 |
2023-06-29 |
Bright Peak Therapeutics Ag |
Modified cd20 antibodies and uses thereof
|
|
WO2023281480A1
(en)
|
2021-07-09 |
2023-01-12 |
Bright Peak Therapeutics Ag |
Conjugates of checkpoint inhibitors with il-2, and uses thereof
|
|
EP4366781A1
(en)
|
2021-07-09 |
2024-05-15 |
Bright Peak Therapeutics AG |
Checkpoint inhibitors conjugated to il-2, and uses thereof
|
|
WO2023023065A1
(en)
|
2021-08-17 |
2023-02-23 |
Werewolf Therapeutics, Inc. |
Inducible cytokine prodrug and pd-1/pd-l1 combination therapy
|
|
CN118119634A
(zh)
|
2021-08-18 |
2024-05-31 |
狼人治疗公司 |
可活化干扰素多肽及其使用方法
|
|
CN118647629A
(zh)
|
2021-09-28 |
2024-09-13 |
苏州格治生物科技有限公司 |
含有TNF-α的免疫缀合物及其相关方法和组合物
|
|
CN118139648A
(zh)
|
2021-10-14 |
2024-06-04 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的替代的PD1-IL7v免疫缀合物
|
|
CA3234552A1
(en)
|
2021-10-20 |
2023-04-27 |
Synthekine, Inc. |
Heterodimeric fc cytokines and uses thereof
|
|
WO2023102493A2
(en)
|
2021-12-01 |
2023-06-08 |
Synthekine, Inc. |
Il10 variants and uses thereof
|
|
EP4452327A1
(en)
|
2021-12-20 |
2024-10-30 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|